Rexahn Pharmaceuticals, Inc.

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Nanotechnology, Chips, etc.
    • Large Molecule
    • Drug Discovery Technologies
      • Bioinformatics
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific

Other Names/Subsidiaries

  • Ocuphire Pharma, Inc.
See more in Biomedtracker

Latest on Rexahn Pharmaceuticals, Inc.

Scrip

Ocuphire Posts Second Phase III Success In Reversing Pupil Dilation

 
• By Joseph Haas

Ocuphire Pharma, Inc. reported statistical significance for its eye drop candidate Nyxol in a second pivotal Phase III study in reversal of pharmacologically induced mydriasis (or pupil dilation). Ma

Scrip

Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates

 
• By Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Will Advance Yumanity Preclinical

Scrip

Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

 
• By Ian Haydock, Anju Ghangurde, Jung Won Shin, and Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . BioDelivery Gains US Rights

Scrip

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

 
• By John Davis

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer